EyePoint Names Leonard Blum to New Role as EVP and GM


WATERTOWN, Mass.—EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing innovative ophthalmic products, has named Leonard M. Blum as executive vice president and general manager, U.S., effective May 14. Blum will be responsible for the launch of Dexycu (dexamethasone intraocular suspension) 9%, an FDA-approved treatment for postoperative inflammation. In addition, he will be responsible for the launch, subject to its FDA approval, of Yutiq (fluocinolone acetonide intravitreal implant), which is a potential treatment for posterior segment uveitis, according to the announcement. The latter product has an FDA action date of Nov. 5, 2018. The two products are expected to launch in the first half of 2019, EyePoint said.

Blum will assume responsibility for all sales, marketing, payor access and trade efforts, as well as the company’s business developments efforts. He has more than 30 years of successful executive and management experience, most recently serving as chief business and commercial officer of Omeros Corp.  

EyePoint, previously known as pSivida Corp., has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases, according to the announcement.